X

Drug Profile

Research programme: HIV vaccines - Novartis

Latest Information Update: 13 Jul 2010

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Class AIDS vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued HIV infections

Most Recent Events

13 Jul 2010 Development discontinued for HIV infections during 2005
20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
19 Feb 2004 Data presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI-2004) have been added to the Viral Infections immunogenicity section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com